Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Seeing The Future: Artificial Intelligence For Age-Related Macular Degeneration
Identifying those at risk of age-related macular degeneration is challenging but new technologies like artificial intelligence pave the way for more accurate diagnosis. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 17, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Feast Your Eyes On DARPins For Vision Loss
DARPins hold great promise for improving outcomes for patients with wet age-related macular degeneration and related conditions. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 14, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Favorable Long-Term Results With Ranibizumab Implant for Neovascular AMD
(MedPage Today) -- The ranibizumab port delivery system (PDS; Susvimo) with 6-month refill maintained noninferiority to monthly intravitreal injections for neovascular age-related macular degeneration (nAMD) out to 2 years, according to updated... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 8, 2023 Category: American Health Source Type: news

A Clear Vision: Anti-VEGF Treatment For Neovascular “Wet” Age-Related Macular Degeneration
This essay delves into the transformative impact of anti-VEGF agents on "wet" age-related macular degeneration. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 5, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
SHANGHAI and BOSTON, July 3, 2023 -- (Healthcare Sales & Marketing Network) -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, today announced that the U.S. F... Regenerative Medicine, Ophthalmology, FDA Skyline Therapeutics, macular degeneration, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2023 Category: Pharmaceuticals Source Type: news

Eyes On The Prize: The Latest Developments in Retinal Gene Therapies
This article will discuss some of the most promising gene therapies for age-related macular degeneration, including ADVM-022, RGX-314, GT-005, and HMR59. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 26, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Visgenx Appoints William Pedranti as Chief Executive Officer
The Company is developing VGX-0111, a gene therapy candidate for Dry Age-related Macular Degeneration (AMD), an aging related disorder and a leading cause of vision loss SAN DIEGO, June 5, 2023 -- (Healthcare Sales & Marketing Network) -- Visgenx, Inc.... Regenerative Medicine, Ophthalmology, Personnel Visgenx , dry AMD, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2023 Category: Pharmaceuticals Source Type: news

iHealthScreen receives FDA 510(k) for AI-enabled eye screening system
The company ' s iPredict System allows providers to detect age-related macular degeneration in the clinical setting. (Source: mobihealthnews)
Source: mobihealthnews - May 25, 2023 Category: Information Technology Source Type: news

iHealthScreen submits AI-enabled eye screening system for 510(k) clearance
The company ' s iPredict System allows providers to detect age-related macular degeneration in the clinical setting. (Source: mobihealthnews)
Source: mobihealthnews - May 25, 2023 Category: Information Technology Source Type: news

Geographic Atrophy: An Expert ’s Perspective
As a retina specialist and ophthalmologist, one expert gives their perspective on geographic atrophy and how to manage it. Get the facts about this advanced form of dry age-related macular degeneration. (Source: WebMD Health)
Source: WebMD Health - May 22, 2023 Category: Consumer Health News Source Type: news

Exclusive: Retina Foundation receives $1 million donation to advance ocular stem cell lab
The donation will be used by researchers to identify personalized stem-cell based therapies and potential cures for age-related macular degeneration. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 18, 2023 Category: Biotechnology Authors: David Moreno Source Type: news

Age-Related Macular Degeneration Highlights From ARVO 2023 Age-Related Macular Degeneration Highlights From ARVO 2023
From ARVO 2023, Dr Neena Haider reports on treatment options for patients with wet age-related macular degeneration, including aflibercept and newer TKI and gene therapies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news

Quantum chemistry protects against age-related macular degeneration
Age-related macular degeneration is a leading cause of vision loss. New research uncovers how the retina protects against it, which could inform treatment. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 10, 2023 Category: Universities & Medical Training Source Type: news

FDA accepts application for Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluidIf approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is currently approved in 60 countries to treat nAMD and DME, with nearly one million doses distributed globallyBasel, 9 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY...
Source: Roche Investor Update - May 9, 2023 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluidIf approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is currently approved in 60 countries to treat nAMD and DME, with nearly one million doses distributed globallyBasel, 9 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY...
Source: Roche Media News - May 9, 2023 Category: Pharmaceuticals Source Type: news